SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Xenova (XNVA)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: nigel bates11/16/2004 8:33:21 AM
  Read Replies (1) of 173
 
Xenova Group PLC Programme Update
(Ouch.)

SLOUGH, U.K., Nov. 16, 2004 (PRIMEZONE) -- Xenova Group plc (LSE: XEN.L - news) (Nadaq:XNVA) (LSE:XEN) today announced that Millennium Pharmaceuticals Inc (NASDAQ: MLNM - news) . (Nasdaq (NASDAQ: news) :MLNM) (Millennium), Xenova's North American partner for the novel DNA targeting agents programme, has informed the Company that as a result of an internal portfolio prioritisation review, it has decided to cease funding the XR5944/XR11576 programme after completion of the on-going Phase I studies.The Phase I programme is underway with patient dosing still ongoing. The trials will be completed as planned and the results of the Phase I trials involving XR5944 and XR11576 are anticipated to be available during H1 2005.

Since Millennium is fully funding the research on these novel DNA targeting agents until the end of Phase I studies, this change will have no immediate cash effect on Xenova. Xenova and Millennium will be entering into discussions shortly regarding the return of the North American commercial rights, which were the subject of a license agreement entered into between the parties in December 2001.

All other programmes within Xenova's portfolio continue unchanged. Millennium has scheduled an R&D meeting in New York taking place today at 09:00 EST (14:00 GMT).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext